Cannabis Pharmaceuticals Market Share, Size, Trends, Industry Analysis Report, By Product (Epidiolex, Marinol, Cesamet, Sativex); By Distribution Channel; By Regions; Segment Forecast, 2020 - 2027
- 公布日期：12月2020年
- Pages: 104
- Format: PDF
- Report ID: PM1773
- Base Year: 2019
- Historical Data: 2016 - 2018
Report Summary
The global cannabis pharmaceuticals market was valued at USD 67.3 million in 2019 and is expected to grow at a CAGR of 75.7% during the forecast period. The key factors responsible for the global market include its transformation from herbal pharmaceuticals to prescription drugs and the use of cannabis-infused drugs for multiple indications such as sleep disorders, inflammation, pain therapies, schizophrenia, genetic disorders, and memory loss disorders such as Alzheimer’s and Multiple Sclerosis.
此外，大麻3.0的出现，这意味着大麻的使用以获得价值和基于感知的结果。该概念侧重于将大麻的使用从传统的吸烟方式转移到药物工业中的加工形式。许可医疗大麻的趋势用于市场上运营的全球付款人。最近在2020年8月，Eqalis Pharmaceuticals是一家新西兰的医疗大麻公司，收到了监管机构的商业许可，为国内市场生产大麻注入药物。
Know more about this report:请求样本页面
例如，在2020年3月，韩国的药品大麻公司，小绿制药公司（LGP），收到了药物管制办公室（ODC）的批准，用于新近的培养，生产医疗大麻和其他辅助活动建造的制造设施位于韩国西部。批准的设施将有9个开花房，计划每年制造大约110,000瓶医疗大麻。该公司正在与德国和英国的经销商签署购买协议，以利用其扩展生产设施。
行业动态
增长司机
The increasing number of clinical trials of cannabis-infused drugs for the different therapeutic areas, specifically the use of Cannabidiol, is positively influencing the market growth. As of June 2018, there were around 400 completed or ongoing clinical trials were carried out. GW Pharmaceuticals sponsored clinically was 40, while Sanofi had 38 active clinical trials.
此外，医生在患有益处和支持临床证据的叙述中，增加患者患者的临床证据。从2019年加拿大卫生的调查中，这是显而易见的。根据调查，大约有13名400名医生，每天为加拿大患者提供2.1克大麻的平均金额。
In addition, several pharmaceuticals companies are focusing on new formulations to reap benefits, being an early mover advantage. For example, in 2018, GW Pharmaceuticals launched EPIDIOLIX oral solution for the treatment of seizures. Most of the companies are using plant-based CBD to innovate new formulations. EPIDIOLIX does not contain a psychoactive compound in marijuana, often known as THC.
Cannabis Pharmaceuticals Market Report Scope
该市场主要基于产品，分销渠道和地区进行分段。
By Product |
By Distribution Channel |
By Region |
|
|
|
Know more about this report:请求样本页面
产品洞察力
基于该产品，全球大麻药品市场分为Epidiolex，Marinol，CeSAMET和SatiTex。2019年，预计SatiTex部分将主导大麻药业市场。部分的高度份额由于被用作患有多发性硬化症的患者痉挛的药物及其在超过21个国家遭受肌肉痉挛的批准。此外，预计持续在脊髓损伤，神经病症和创伤后应激障碍之类的其他条件下使用的临床试验，以平衡其在研究期间的优势。
While the Epidiolex segment is projected to exhibit the highest growth rate over the study timeframe. This is the first cannabis-infused pharmaceuticals approved by the FDA. Moreover, in 2018, it was indicated for Lennox-Gastaut Syndrome (LGS) and Dravet syndrome treatments after promising clinical trial results showing a reduction in seizures. Thus, its high effectiveness, expected to increase its demand in the coming years.
Insight by Distribution Channel
基于分销渠道,市场是categorized into hospitals, online pharmacies, and retail. In 2019, the hospital segment is expected to be the largest among all the segments. Segment’s high share is due to the exclusive strategic partnerships among manufacturers, and high sale of cannabis-infused medicines from the hospital pharmacies, as prescribed by the physicians. Most of the private hospitals have their in-house medicine disbursal outlet, located within the hospital.
The retail sales segment is expected to exhibit the highest growth rate over the study period. Factors responsible for this would be favorable industry events. For instance, in October 2020, the Colorado-based company, BDSA, provider sales tracking services, has increased its offering to the Cannabis industry. It partnered with Canada based technology company Buddi.
地理概述
North America is the largest revenue contributor in the cannabis pharmaceuticals market. The North American region, in particular the U.S., is experiencing adverse COVID outcomes. While the United States has not federally legalized cannabis for medical or recreational use, 33 U.S. states have enacted laws legalizing cannabis in some form for medical use, and 10 states have legalized cannabis for adult use.
An additional 14 states allow the use of CBD a non-psychoactive cannabinoid with strong therapeutic value on a very limited basis. Despite federal illegality, cannabis use in the U.S. is so widespread at the municipal level that it is increasingly becoming a low priority for law enforcement and the courts. As result, not only do Americans hold very progressive views on cannabis legalization 62 percent believe it should be nationally legal the country has also led the world in cannabis innovation, with the creation of new genetics, cultivation techniques, derivative products, and ingestion methods.
美国外交始终以其“毒品战争”为其国际盟友撒谎。美国与联合国和有关国际机构进行了国际举措，通过国际条约，有效地禁止全球大麻结构。这种政策，以及加拿大和其他县如何解释它们的方式，正在推动关于大麻改革的全球辩论。
拉丁美洲地区的许多国家通过高度监管的行业推出法律医疗大麻。必威体育app手机版官网八个国家合法化医疗用途：阿根廷，巴西，智利，哥伦比亚，墨西哥，巴拉圭，秘鲁和乌拉圭。该地区唯一一个有合法化的娱乐使用的国家是乌拉圭，尽管预计今年墨西哥将合法化成人使用计划。
Uruguay’s adult-use reform was enacted in 2014, and the country has since also established a regulated medical cannabis program. The stated goals of adult-use legalization were to reduce violence associated with drug trafficking and to promote public health. The respective country’s government strongly controls the cultivation, processing, and dispensing of both medical and recreational cannabis.
Competitive Insight
Key players operating in the global market include GW Pharmaceuticals, AbbVie Inc., Valeant Pharmaceuticals, Insys Therapeutics, Inc., Corbus Pharmaceuticals, Teva Pharmaceutical, Johnson & Johnson, Avicanna, Solvay Pharmaceuticals, Cannabics Pharmaceuticals, Portola Pharmaceuticals, Kao Corporation, Ogeda S.A., Pfizer, and Bristol-Myers Squibb.
